Affordable Access

The use of caspofungin in HIV-infected individuals.

Authors
  • Waters, Laura
  • Nelson, Mark
Type
Published Article
Journal
Expert Opinion on Investigational Drugs
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jun 01, 2007
Volume
16
Issue
6
Pages
899–908
Identifiers
PMID: 17501701
Source
Medline
License
Unknown

Abstract

Fungal infections are a significant cause of HIV-related morbidity and mortality, particularly in the developing world, but also in countries with access to highly active antiretroviral therapy. New agents are essential to improve present efficacy rates, particularly in cases of drug resistance. Caspofungin is a new antifungal from the echinocandin class and is licensed for the treatment of candidal infections and as a second-line therapy for invasive aspergillosis. In this paper, the pharmacology, interaction and susceptibility data for this agent are reviewed and studies supporting the use of this agent in HIV-infected individuals are examined. Finally, evidence for the use of caspofungin for the treatment of Pneumocystis jiroveci pneumonia, an unlicensed indication, including a case series from our own unit is explored.

Report this publication

Statistics

Seen <100 times